The antibody MEM-97 reacts with an extracellular epitope on CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
Faldyna, Samankova, Leva, Cerny, Oujezdska, Rehakova, Sinkora: "Cross-reactive anti-human monoclonal antibodies as a tool for B-cell identification in dogs and pigs." dans: Veterinary immunology and immunopathology, Vol. 119, Issue 1-2, pp. 56-62, (2007) (PubMed).
Brdicková, Brdicka, Angelisová, Horváth, Spicka, Hilgert, Paces, Simeoni, Kliche, Merten, Schraven, Horejsí: "LIME: a new membrane Raft-associated adaptor protein involved in CD4 and CD8 coreceptor signaling." dans: The Journal of experimental medicine, Vol. 198, Issue 10, pp. 1453-62, (2003) (PubMed).
Szöllósi, Horejsí, Bene, Angelisová, Damjanovich: "Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 157, Issue 7, pp. 2939-46, (1996) (PubMed).
Strobl, Takimoto, Majdic, Fritsch, Scheinecker, Höcker, Knapp: "Myeloperoxidase expression in CD34+ normal human hematopoietic cells." dans: Blood, Vol. 82, Issue 7, pp. 2069-78, (1993) (PubMed).
Antigène
CD20 (MS4A1)
(Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
MS4A1,CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.,B1, S7, MS4A, Bp35, CVID5, LEU-16